UNSPSC 51182440: Cholecalciferol/Risedronate sodium or risedronic acid

Cholecalciferol/Risedronate sodium or risedronic acid is a fixed-dose combination and is indicated for the treatment and prevention of osteoporosis.

UNSPSC 51182440 Cholecalciferol/Risedronate sodium or risedronic acid is a Commodity code for pharmaceutical products that state and local governments procure through health departments, emergency medical services, county health systems, and cooperative purchasing alliances; recent opportunities show minimal activity directly under this specific code, with the available records dominated by networking events, administrative notices, and solicitations tagged to adjacent pharmaceutical categories rather than this precise combination of bone-health medications.

The source contains no recent state or local solicitations explicitly seeking cholecalciferol/risedronate sodium or risedronic acid as a line item or primary deliverable. Of the twenty-two records in the opportunities block, only one—MMCAP's January 20, 2026 Request for Proposal for Generic Multi Source Pharmaceuticals and OTC Products—touches pharmaceutical procurement at scale, but that solicitation addresses a broad catalog of generic and over-the-counter products distributed through authorized wholesalers to state and local government facilities across multiple states, with no indication that bone-health combination therapies are among the targeted products. The remaining records span vendor networking forums (Marion County Reverse Trade Show, Williamson County Vendor Forum, Collin County Meet & Greet, FAPPO Annual Trade Show, Pasco County How to Do Business Event), informational events (Indian River County Vendor Open House, Richardson Purchasing Survey), and unrelated procurement activities (engineering services, clinic wellness services, drug standards for forensic labs, naloxone procurement, medical oxygen rental, pharmacy benefits network qualification). The code shows no substantive recent procurement volume or clear issuing-body concentration. Without recent competitive solicitations naming this code and explicitly seeking cholecalciferol or risedronate sodium products, pursuit under this code carries minimal near-term opportunity signal.